EUVIMEDEUVIMED entdecken
Open Access

Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation

Zhili Zhuo, Dongni Zhang, Wenping Lu, Xiaoqing Wu, Yongjia Cui, Weixuan Zhang, Mengfan Zhang

Oncology Research · 2024

DOI: 10.32604/or.2024.047257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Zhili Zhuo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China. Hauptthemen laut MEDLINE: Artemisinins, Breast Neoplasms, Computational Biology, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the leading cause of cancer-related deaths in women worldwide, with Hormone Receptor (HR)+ being the predominant subtype. Tamoxifen (TAM) serves as the primary treatment for HR+ breast cancer. However, drug resistance often leads to recurrence, underscoring the need to develop new therapies to enhance patient quality of life and reduce recurrence rates. Artemisinin (ART) has demonstrated efficacy in inhibiting the growth of drug-resistant cells, positioning art as a viable option for counteracting endocrine resistance. This study explored the interaction between artemisinin and tamoxifen through a combined approach of bioinformatics analysis and experimental validation. Five characterized genes (ar, cdkn1a, erbb2, esr1, hsp90aa1) and seven drug-disease crossover genes (cyp2e1, rorc, mapk10, glp1r, egfr, pgr, mgll) were identified using WGCNA crossover analysis. Subsequent functional enrichment analyses were conducted. Our findings confirm a significant correlation between key cluster gene expression and immune cell infiltration in tamoxifen-resistant and -sensitized patients. scRNA-seq analysis revealed high expression of key cluster genes in epithelial cells, suggesting artemisinin's specific impact on tumor cells in estrogen receptor (ER)-positive BC tissues. Molecular target docking and in vitro experiments with artemisinin on LCC9 cells demonstrated a reversal effect in reducing migratory and drug resistance of drug-resistant cells by modulating relevant drug resistance genes. These results indicate that artemisinin could potentially reverse tamoxifen resistance in ER-positive breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArtemisininsBreast NeoplasmsComputational BiologyDrug Resistance, NeoplasmReceptors, EstrogenTamoxifenFemaleHumansAntineoplastic Agents, HormonalCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticMolecular Docking Simulation

Stichwörter der Autor:innen

ArtemisininBreast cancerTamoxifen resistance

Substanzen

Antineoplastic Agents, HormonalartemisininArtemisininsReceptors, EstrogenTamoxifen

Autor:innen und Institutionen

  • Department of Oncology, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China.

Zitieren

APA

Zhuo, Z., Zhang, D., Lu, W., Wu, X., Cui, Y., Zhang, W., & Zhang, M. (2024). Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation. Oncology Research. https://doi.org/10.32604/or.2024.047257

Vancouver

Zhuo Z, Zhang D, Lu W, Wu X, Cui Y, Zhang W, et al. Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation. Oncology Research. 2024. doi:10.32604/or.2024.047257

BibTeX
@article{Zhuo2024,
  author = {Zhuo, Zhili and Zhang, Dongni and Lu, Wenping and Wu, Xiaoqing and Cui, Yongjia and Zhang, Weixuan and Zhang, Mengfan},
  title = {Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation},
  journal = {Oncology Research},
  year = {2024},
  doi = {10.32604/or.2024.047257}
}
Kostenlos starten →